Borbolla SI, Zertuche DL, Díaz GEJ, Leopoldo RWF

Language: Spanish
References: 20
Page: 253-257
PDF size: 206.25 Kb.

ABSTRACT

Psoriasis is an immune-mediated and systemic inflammatory disorder that affects the skin and various organs. Its exact etiology is unknown, although it has predisposing genetic and epigenetic markers, in addition to the fundamental role of the immune system in its progression. It has effect on different systems, therefore, the adipose tissue has been shown to suffer dysfunction leading to insulin resistance and therefore to the metabolic syndrome, development of atherosclerosis and increased cardiovascular risk. Inflammation is the main pathophysiological factor in atherosclerosis, therefore the association of IL-17 with endothelial dysfunction, cardiovascular diseases and psoriasis has been studied where there is probably a positive correlation, according to the available evidence. In patients with this illness, heart diseases are the first or second cause of mortality, so high that mortality worldwide is 46%. There are alterations in the different types of cholesterol, triglycerides, lipoproteins and Apo A1, which together with autoimmune inflammation develop atherosclerosis and increase cardiovascular risk, which is also promoted by oxidation-modified lipoproteins and oxidized low-density lipoproteins. Coronary artery atherosclerosis has been discovered to be an important risk component for ischemic heart disease, patients with psoriasis have been found to have a higher prevalence and severity in coronary heart disease.

REFERENCES

1. Choudhary S, Patel R, Pradhan D, Deval R, Singh H, Thomas G et al. Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies. 3 Biotech. 2020; 10 (3): 104.

2. Espinoza HCJ, Kresch TN, Vega MME, Lacy NRM, Lacy NMC, Springall VR et al. Psoriasis y riesgo cardiovascular. Uso de la escala de riesgo Framingham y nuevos biomarcadores para la predicción de mortalidad cardiovascular en pacientes con psoriasis. Dermatología Cosmética, Médica y Quirúrgica. 2012; 10 (4): 301.

3. Packer M. Epicardial adipose tissue inflammation can cause the distinctive pattern of cardiovascular disorders seen in psoriasis. Am J Med. 2020; 133 (3): 267-272.

4. Curco N, Barriendos N, Barahona MJ, Arteaga C, García M, Yordanov S et al. Factors influencing cardiometabolic risk profile in patients with psoriasis. Australas J Dermatol. 2018; 59 (2): e93-e98.

5. Verma S, Bhatt DL. Does interleukin-17A blockade have a potential clinical role to reduce cardiovascular risk in psoriasis? Can J Cardiol. 2020; 36 (1): 24-26.

6. Von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019; 10: 3096.

7. Makavos G, Ikonomidis I, Andreadou I, Varoudi M, Kapniari I, Loukeri E et al. Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis. Can J Cardiol. 2020; 36 (1): 100-111.

8. Egeberg A, Gisondi P, Carrascosa J, Warren R, Mrowietz U. The role of the IL-23/Th17 pathway in cardio-metabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020; 34 (8): 1695-1706.

9. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017; 76 (3): 377-390.

10. Asha K, Singal A, Sharma SB, Arora VK, Aggarwal A. Dyslipidaemia & oxidative stress in patients of psoriasis: Emerging cardiovascular risk factors. Indian Journal of Medical Research. 2017; 146 (6): 708-713.

11. Hu SC-S, Lan C-CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017; 18 (10): 2211.

12. Siddiqi HK, Ridker PM. Psoriasis and atherosclerosis: where inflammation and lipid biology meet. Circulation Research. 2018; 123: 1183-1184.

13. Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J of Mol Sci. 2018; 19 (1): 58.

14. Fernández-Torres R, Pita-Fernández S, Fonseca E. Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores. J Eur Acad Dermatol Venereol. 2013; 27 (12): 1566-1570.

15. Myasoedova E, Manu AVB, Matteson EL, Maradit KH, McEvoy MT, Crowson CS. Cardiovascular risk in psoriasis: a population-based analysis with assessment of the Framingham risk score. Scientifica (Cairo). 2013; 2013: 371569.

16. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco A, Aguilar M et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013; 27 (11): 1387-1404.

17. Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN et al. Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2017; 31 (6): 992-1003.

18. Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate to severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography. J Am Acad Dermatol. 2019; 80 (5): 1322-1331. doi: 10.1016/j.jaad.2018.03.011.

19. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377 (12): 1119-1131.

20. Skendros P, Papagoras C, Lefaki I, Giatromanolaki A, Kotsianidis I, Speletas M et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2017; 176 (1): 212-215.